Shukra Pharmaceuticals Q2 FY27 Results: Profit Rises to ₹1,601 Lakhs
Shukra Pharmaceuticals reported strong Q2 FY27 results. Consolidated net profit surged to ₹1,601.20 lakhs (₹16.01 crore) from ₹237.81 lakhs. Standalone net profit also rose to ₹1,601.20 lakhs from ₹237.81 lakhs. Total income increased to ₹4,477.58 lakhs from ₹759.00 lakhs. The company has also changed its name to Shukra Medtech Limited.
The significant year-on-year growth in profits and revenue, along with the company's name change, are material events that are likely to have a high impact on investor perception and the company's valuation.
The company reported a substantial increase in net profit and total income for both the quarter and half-year ended September 30, 2026, compared to the previous year, indicating positive financial performance.
Shukra Pharmaceuticals Limited (now Shukra Medtech Limited) announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors approved these results on November 4, 2026.
For the quarter ended September 30, 2026, the company reported a net profit of ₹1,601.20 lakhs (₹16.01 crore) on a consolidated basis, a significant increase from ₹237.81 lakhs (₹2.38 crore) in the same period last year. Standalone net profit stood at ₹1,601.20 lakhs (₹16.01 crore) compared to ₹237.81 lakhs (₹2.38 crore) in the prior year quarter.
Total income from operations for the quarter was ₹4,477.58 lakhs (₹44.78 crore), up from ₹759.00 lakhs (₹7.59 crore) in the corresponding quarter of the previous year. The company also reported a robust half-year performance, with consolidated net profit at ₹3,104.18 lakhs (₹31.04 crore) and standalone net profit at ₹3,104.18 lakhs (₹31.04 crore).
The company's name was changed from Shukra Pharmaceuticals Limited to Shukra Medtech Limited, effective October 12, 2026. During the half-year, convertible warrants were converted into equity shares, increasing the share capital.
What to do with a filing like this
Shukra Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shukra Pharmaceuticals Limited. Read the original for the full detail.